Borderline Resectable Pancreatic Adenocarcinoma Clinical Trials

20 clinical trials for Borderline Resectable Pancreatic Adenocarcinoma across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma — RECRUITING · PHASE2
• Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma — RECRUITING · PHASE1
• PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) — RECRUITING · PHASE1
• HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation — RECRUITING · PHASE2
• Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) — RECRUITING · PHASE1
• A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer — RECRUITING
• Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma — RECRUITING · PHASE2
• Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer — RECRUITING
• Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer — COMPLETED · PHASE2
• Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer — COMPLETED · PHASE1
• NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study — WITHDRAWN · PHASE2
• Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer — NOT_YET_RECRUITING · PHASE2
• A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer — TERMINATED · PHASE2
• Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) — ACTIVE_NOT_RECRUITING
• Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer — COMPLETED · PHASE1
• Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma — OTHER · PHASE2
• Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer — COMPLETED · PHASE1
• Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma — OTHER · NA

Refine this search